Astellas Pharma vs Daiichi Sankyo Company: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Astellas Pharma Inc. (4503.JP)

Q3 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

August 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Latest15 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Daiichi Sankyo Company, Limited (4568.JP)

Q3 202626 Jun – 17 Sep 2026

▲3▼1

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and Strong Revenue

EU Approvals for Datroway and Enhertu Datroway received EU first-line TNBC approval, while Enhertu gained EU tumor-agnostic approval, triggering a $25M AstraZeneca milestone. These expand treatment options and validate the ADC platform.
These approvals are major regulatory wins that open new markets and drive revenue potential.
Enhertu Reimbursement and Trial Success Enhertu secured NHS England reimbursement for HER2-low breast cancer after earlier rejection and showed strong first-line lung cancer data. This improves patient access and supports future growth.
Reimbursement and positive trial results directly impact sales and market confidence.
Strong Q1 Revenue and Raised Guidance Q1 revenue jumped 21% to ¥574.7B, prompting raised full-year guidance. This reflects robust business performance and management confidence.
Revenue growth and guidance raise are key financial indicators that drive investor sentiment.
Reimbursement Uncertainty and Undisclosed Economics The NHS pricing deal could still fall through, and confidential discounts obscure the exact financial benefit of expanded access. These factors temper the positive outlook.
These risks could limit the financial upside from approvals and reimbursements.

August 202631 Jul – 17 Sep 2026

▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.
New approval directly expands the commercial opportunity for a key growth drug.
Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.
Guidance raise signals stronger-than-expected business momentum and earnings power.
Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.
Late-stage trial success increases the probability of a new major indication for Enhertu.
NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.
Reimbursement win widens patient access and commercial reach for a core drug.

Latest31 Jul – 17 Sep 2026

▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.
New approval directly expands the commercial opportunity for a key growth drug.
Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.
Guidance raise signals stronger-than-expected business momentum and earnings power.
Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.
Late-stage trial success increases the probability of a new major indication for Enhertu.
NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.
Reimbursement win widens patient access and commercial reach for a core drug.

July 202626 Jun – 24 Jul 2026

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.
New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.
Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.
New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.
NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.
New pricing agreement would unlock a major market and signal broader reimbursement momentum.
Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.
New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

26 Jun – 24 Jul 2026

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.
New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.
Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.
New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.
NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.
New pricing agreement would unlock a major market and signal broader reimbursement momentum.
Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.
New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.